PBU The Pension Fund of Early Childhood & Youth Educators Purchases New Shares in Medtronic PLC $MDT

PBU The Pension Fund of Early Childhood & Youth Educators purchased a new stake in shares of Medtronic PLC (NYSE:MDT) during the 4th quarter, Holdings Channel reports. The institutional investor purchased 105,030 shares of the medical technology company’s stock, valued at approximately $10,089,000.

Other hedge funds also recently made changes to their positions in the company. Lodestone Wealth Management LLC bought a new stake in shares of Medtronic during the fourth quarter valued at approximately $27,000. Anfield Capital Management LLC boosted its position in shares of Medtronic by 410.7% during the fourth quarter. Anfield Capital Management LLC now owns 286 shares of the medical technology company’s stock valued at $27,000 after purchasing an additional 230 shares in the last quarter. Board of the Pension Protection Fund bought a new stake in shares of Medtronic during the fourth quarter valued at approximately $29,000. GoalVest Advisory LLC bought a new stake in shares of Medtronic during the fourth quarter valued at approximately $29,000. Finally, Imprint Wealth LLC bought a new stake in shares of Medtronic during the third quarter valued at approximately $31,000. 82.06% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several equities research analysts recently weighed in on MDT shares. Sanford C. Bernstein dropped their price target on Medtronic from $112.00 to $97.00 and set an “outperform” rating on the stock in a research report on Thursday. Daiwa Securities Group lowered their price objective on Medtronic from $117.00 to $115.00 and set a “buy” rating for the company in a research note on Friday, February 27th. JPMorgan Chase & Co. lowered their price objective on Medtronic from $100.00 to $86.00 and set a “neutral” rating for the company in a research note on Thursday. Citigroup lowered their price objective on Medtronic from $117.00 to $110.00 and set a “buy” rating for the company in a research note on Tuesday, April 7th. Finally, Piper Sandler lowered their price objective on Medtronic from $91.00 to $85.00 and set a “neutral” rating for the company in a research note on Thursday. Seventeen analysts have rated the stock with a Buy rating and eleven have assigned a Hold rating to the company’s stock. According to MarketBeat.com, Medtronic currently has a consensus rating of “Moderate Buy” and a consensus price target of $99.00.

Key Stories Impacting Medtronic

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Medtronic’s fiscal Q4 results beat revenue expectations and showed continued year-over-year growth, while management signaled confidence in the company’s FY26/FY27 growth outlook and new product platforms. Medtronic (MDT) Climbs 5.7% on Stellar Q4
• Positive Sentiment: BTIG upgraded Medtronic to Buy with a $90 target, citing a strong revenue beat and improving organic growth, while other firms such as TD Cowen and RBC reaffirmed bullish ratings. Wall Street May Be Mispricing Medtronic, Analyst Says
• Positive Sentiment: Medtronic expanded its relationship with Retia Medical to distribute the Argos Cardiac Output Monitor across Western Europe, adding to its cardiovascular portfolio and international reach. Retia Medical Expands Distribution of Argos® Cardiac Output Monitor to Western Europe with Medtronic
• Positive Sentiment: Medtronic also announced a higher quarterly dividend, signaling confidence in cash generation and shareholder returns. Medtronic (MDT) Climbs 5.7% on Stellar Q4
• Neutral Sentiment: Several brokerages lowered price targets after earnings, but most still kept Buy/Outperform or Hold/Neutral ratings, suggesting a reset in expectations rather than a major change in long-term views. Rothschild & Co Redburn cuts Medtronic price target
• Neutral Sentiment: Analyst roundups highlighted that Wall Street’s average recommendation remains Buy, but those consensus ratings are often viewed as overly optimistic and not always predictive. Is Medtronic (MDT) a Buy as Wall Street Analysts Look Optimistic?
• Negative Sentiment: Medtronic is still dealing with ongoing cardiovascular device recalls tied to potential sterile barrier issues, which could weigh on investor sentiment and create some execution risk. Medtronic Balances Hugo Robotics Expansion With Ongoing Cardiovascular Device Recalls

Medtronic Stock Down 0.3%

Shares of NYSE:MDT opened at $81.66 on Friday. The stock has a fifty day simple moving average of $81.46 and a two-hundred day simple moving average of $92.04. The stock has a market capitalization of $104.84 billion, a price-to-earnings ratio of 21.89, a PEG ratio of 1.99 and a beta of 0.58. Medtronic PLC has a 12-month low of $73.31 and a 12-month high of $106.33. The company has a current ratio of 2.54, a quick ratio of 1.87 and a debt-to-equity ratio of 0.57.

Medtronic (NYSE:MDT) last announced its quarterly earnings data on Wednesday, June 3rd. The medical technology company reported $1.55 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.54 by $0.01. The business had revenue of $9.81 billion during the quarter, compared to analysts’ expectations of $9.62 billion. Medtronic had a return on equity of 14.61% and a net margin of 13.20%.The firm’s quarterly revenue was up 9.9% compared to the same quarter last year. During the same quarter in the previous year, the business earned $1.62 earnings per share. Medtronic has set its FY 2027 guidance at 5.900-6.000 EPS. On average, research analysts anticipate that Medtronic PLC will post 5.94 earnings per share for the current fiscal year.

Medtronic Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, July 17th. Shareholders of record on Friday, June 26th will be issued a $0.72 dividend. This represents a $2.88 dividend on an annualized basis and a dividend yield of 3.5%. The ex-dividend date of this dividend is Friday, June 26th. This is a positive change from Medtronic’s previous quarterly dividend of $0.71. Medtronic’s dividend payout ratio is 76.14%.

Medtronic Company Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).